相关实验视频

Updated: Jul 18, 2025

Mechanical Stimulation-induced Calcium Wave Propagation in Cell Monolayers: The Example of Bovine Corneal Endothelial Cells

Mechanical Stimulation-induced Calcium Wave Propagation in Cell Monolayers: The Example of Bovine Corneal Endothelial Cells

Published on: July 16, 2013

携带阿托瓦斯塔丁的类两抗角膜新血管化

Elena Sánchez-López^1,2,3,4, Maria José Gómara⁴, Isabel Haro⁴

¹Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028, Barcelona, Spain.

Nanomedicine (London, England)

|August 23, 2023

概括

在双纳米载体中的局部阿托瓦斯塔丁 (ATV) 有效地治疗角膜新血管化. 这种新型配方具有良好的眼睛耐受性,具有抗血管和抗炎性质,为这种危及视力的疾病提供了有前途的治疗方法.

科学领域:

眼科医生眼科眼科
纳米技术纳米技术
药理学药理学是指药理学的学科.

背景情况:

角膜新血管化 (CNV) 是视力丧失的一个重要原因.
抗血管新生和抗炎疗法对于管理CNV至关重要.
局部阿托瓦斯塔丁 (ATV) 是一种潜在的治疗药物.

研究的目的:

开发和评估用于局部眼部输送阿托瓦斯塔丁 (ATV) 的类两纳米载体.
评估ATV载纳米载体在治疗角膜新血管化的抗血管和抗炎疗效.
为了确定新型ATV配方的眼睛耐受性和药物释放特征.

主要方法:

三种具有不同链长度 (mC16,dC16,qC16) 和Tat47-57.7结合的两性蛋白的合成和表征.
将阿托瓦斯塔丁 (ATV) 封装到合成的两中.
药物加载效率的评估,体外药物释放,眼睛耐受性,抗炎和抗血管活动.

主要成果:

与mC16和dC16变体相比,装有ATV的qC16-Tat47-57纳米载体表现出更高的封装效率和更明确的纳米结构.
ATV-qC16-Tat47-57显示持续的药物释放和有利的眼膜耐受性.
在ATV-qC16-Tat47-57配方有效抑制角膜新血管化和减少眼部炎症.

结论:

ATV-qC16-Tat47-57代表了一种非常有希望的局部纳米药物,用于对抗角膜新血管化.
开发的双纳米载体系统增强了ATV的输送和有效性,用于眼睛表面疾病.
这项研究强调了定制纳米载体在改善视力威胁的角膜疾病治疗方面的潜力.

关键词:

血管新生是因为血管新生.亚托尔瓦斯塔丁是一种药物输送是药物输送的过程.眼部炎症眼部炎症类两类动物.

更多相关视频

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

The Corneal Micropocket Assay: A Model of Angiogenesis in the Mouse Eye

The Corneal Micropocket Assay: A Model of Angiogenesis in the Mouse Eye

Published on: August 16, 2014

相关概念视频

COP Coated Vesicles

COP Coated Vesicles

Membrane-enclosed structures called vesicles transport proteins and lipids across the cell. The vesicles derive their cargo from the plasma membrane, Golgi, ER, or endosome. Coated vesicles are spherical, protein-coated carriers with a 50–100 nm diameter that mediate bidirectional transport between the ER and the Golgi. The distribution of proteins between the ER and Golgi complex is dynamic and is maintained by different coated vesicles. Their formation is driven by the assembly of...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...